Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults by Kemppinen, Anu et al.
This is a repository copy of Randomised, double-blind, placebo controlled multi-centre 
study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of 
irritable bowel syndrome with diarrhoea (IBS-D) in adults.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/156956/
Version: Published Version
Article:
Kemppinen, Anu, Howell, Carol, Allgar, Victoria orcid.org/0000-0002-5228-2623 et al. (8 
more authors) (2020) Randomised, double-blind, placebo controlled multi-centre study to 
assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel
syndrome with diarrhoea (IBS-D) in adults. Trials. pp. 1-14. ISSN 1745-6215 
https://doi.org/10.1186/s13063-020-4069-x
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
STUDY PROTOCOL Open Access
Randomised, double-blind, placebo
controlled multi-centre study to assess the
efficacy, tolerability and safety of
Enterosgel® in the treatment of irritable
bowel syndrome with diarrhoea (IBS-D) in
adults
Anu Kemppinen1* , Carol Howell2, Victoria Allgar3, Matthew Dodd4, John Gregson4, Charles Knowles5,
John McLaughlin6,7, Preeti Pandya8, Peter Whorwell6,9, Elena Markaryan2 and Yan Yiannakou10
Abstract
Background: Irritable bowel syndrome (IBS) with diarrhoea (IBS-D) is a common and chronic condition that can
significantly impair quality of life. The emergence of new drugs for IBS-D has been slow and there is a need for
new treatments, including drug-free treatments, which are easy to use and suitable for different patient groups.
Currently available drug-free treatments include Enterosgel®, an intestinal adsorbent approved for use in IBS-D and
acute diarrhoea and available over-the-counter in the UK and 30 countries worldwide. The aim of this randomised,
double-blind, placebo-controlled, multi-centre study is to test the efficacy and safety of Enterosgel® compared to
placebo in symptomatic treatment in IBS-D.
Methods/design: We will recruit 430 participants with IBS-D from approximately 30 primary and secondary care
sites in England. Participants meeting the required abdominal pain and stool consistency criteria over a 2-week
screening period will be randomly allocated to receive blinded treatment (Enterosgel® or placebo) for 8 weeks. This
will be followed by an 8-week open-label treatment phase with Enterosgel®. Participants will be allowed to adjust
their daily dosage during both phases based on their symptoms. Participants will then return to standard care and
those who responded to treatment will receive a follow-up call 8 weeks later. Co-medication with loperamide will
be permitted and use recorded. The primary outcome measure is the percentage of participants defined as
responders for abdominal pain and stool consistency during at least 4 weeks in the 8-week blinded phase.
Secondary outcome measures include stool frequency, stool consistency, abdominal pain, bloating, urgency,
adequate relief, questionnaire scores and rescue medication use. Exploratory outcomes will be assessed in subsets
of participants including qualitative and quantitative data on faecal microorganisms and biomarkers and gut-related
measurements from magnetic resonance imaging data.
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Discussion: This is the first large scale randomised controlled trial investigating Enterosgel® in IBS-D. A study design
with blinded phase followed by an open-label phase was chosen to encourage participation and study completion.
Demonstrating that Enterosgel® is effective and safe in IBS-D could encourage adoption by patients and healthcare
professionals and foster future clinical trials assessing its use in related conditions.
Trial registration: ISRCTN17149988. Prospectively registered on 14 November 2017.
Keywords: Clinical trial, Diarrhoea, Enterosgel, Intestinal adsorbent, Irritable bowel syndrome, Medical device,
Placebo-controlled, Randomised controlled trial
Background
Irritable bowel syndrome (IBS) is a common chronic
functional bowel condition characterised by symptoms
of abdominal pain and/or discomfort associated with al-
tered bowel habits, in the absence of a structural or or-
ganic cause [1, 2]. The Rome IV criteria provide the
latest diagnostic criteria for IBS [3] and its three main
subtypes, i.e. IBS with diarrhoea (IBS-D), IBS with con-
stipation (IBS-C) and mixed IBS (IBS-M). The specific
cause of the disorder is not fully understood [4, 5], but
among other factors may include genetic disposition, gut
immune dysfunction, immune activation, gut dysbiosis,
infective and dietary triggers and changes to gut perme-
ability [6–8].
IBS is common worldwide, with an estimated prevalence
globally of 11.2% [9, 10], although a more recent study
based on the Rome IV criteria for diagnosis suggests a re-
duced estimate of around 5.0% [11]. In the UK, the preva-
lence is estimated to be between 10% and 20% [12]. It
occurs in all age groups, including children and the elderly,
although it predominantly affects adults of working age.
Internationally, the overall prevalence of IBS in women is
67% higher than in men, although there are differences in
the sex-specific prevalence between geographic regions [9].
The prevalence of each subtype can vary depending on the
classification used. According to the World Gastroenter-
ology Organisation, up to one-third of cases are IBS-D, up
to one-third of cases are IBS-C and IBS-M accounts for up
to one-third to one-half of cases [13].
IBS imposes a substantial burden on society, impacting
on patients’ quality of life, work productivity and social
activities, as well as on direct and indirect healthcare
costs. In the UK, direct healthcare costs include an esti-
mated eight to ten general practice (GP) visits per year
[14] and associated visits for the 29% of IBS patients
who are referred to secondary care specialists before
returning to primary care for their long-term manage-
ment [15]. Overall healthcare costs for IBS are compar-
able to those of other chronic diseases with a similar
prevalence, such as congestive heart failure, hyperten-
sion, asthma and migraine [16].
IBS is a challenging condition to treat mainly as a re-
sult of its complex multi-factorial nature. Currently, no
single universally effective approach is available for the
management of IBS [13], but lifestyle or dietary changes
are often implemented as the first step of management.
For example, the low Fermentable, Oligo-, Di-, Mono-
saccharides and Polyols (FODMAP) diet can help symp-
toms [12] but can be difficult to implement without sup-
port from a dietician. Probiotic use is also becoming
more common and has shown to improve symptoms in
patients with IBS-D [17]. Potential treatment targets in-
clude mediators such as histamine and serotonin, which
are postulated to play a causative role in IBS, and bacter-
ial products and bile acids, which also have been impli-
cated in the generation of IBS symptoms [7, 8].
Medications for treating IBS-related symptoms include
antispasmodics, psychotropic agents, bulking agents and
5-HT receptor antagonists. However, many of these
drugs have proven to be inadequate for the relief of
symptoms and some have safety issues [18]. Less than
one-third of patients with IBS are satisfied with their
current therapy, with only 45% describing their prescrip-
tion drugs as “effective” [19]. Minimal understanding of
the pathophysiological aspects of the condition, poorly
designed studies providing unconvincing evidence, in-
consistent literature on IBS treatments and high placebo
response rates (30–80%) in short term studies [20–22]
are all likely to contribute to the lack of effective treat-
ments. There is, therefore, a need for well-designed clin-
ical trials on new therapies for IBS-D.
Previous clinical studies on intestinal adsorbents have
shown some improvement in the symptoms of IBS-D,
but are likely to have been underpowered for many im-
portant outcome measures [23, 24]. The rationale for
the use of intestinal adsorbents in the management of
IBS symptoms is their ability to bind to various media-
tors and toxins and remove them from the gastrointes-
tinal tract in the stools. There is also evidence from
research on the intestinal adsorbent dioctahedral smect-
ite for enhancement of the intestinal barrier function,
which counteracts disruption from pro-inflammatory
cytokines [25, 26]. One of the intestinal adsorbents
approved for use in IBS-D and available over-the-
counter in the UK is Enterosgel®, which is a drug-free
treatment developed for binding toxins and other
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harmful substances in the gastrointestinal tract [27]. It is
suitable for different patient groups, including children
and the elderly. Although there has been extensive re-
search on Enterosgel®, including two pilot studies in IBS-
D reporting a normalisation of stool frequency and form
and decrease in bodily pain [28, 29], and a UK based
study in acute diarrhoea [30], so far none of the con-
ducted studies have included a placebo control arm. The
difficulty has been that gel-like substances with a
consistency similar to commercially available Enterosgel®
(for example gelatin or starch based) could potentially
have effects in the gastrointestinal tract and their suit-
ability for use as a placebo would require validation. This
randomised, double-blind, placebo-controlled, multi-
centre study will use an innovative approach to over-
come this challenge. The aim is to test the efficacy and
safety of Enterosgel® over placebo in symptomatic treat-
ment in 430 adults with IBS-D diagnosed according to
the Rome IV criteria.
Methods/design
Study design
This will be a multi-centre, parallel arm, randomised,
double-blind, placebo-controlled trial to evaluate the ef-
ficacy, tolerability and safety of a medical device, Enter-
osgel®, in the treatment of IBS-D in adults (Fig. 1). The
study involves a 2-week screening phase, after which eli-
gible participants are randomised to blinded treatment
(Enterosgel® or placebo) for 8 weeks. Following the
double-blind treatment phase, all participants will re-
ceive open-label Enterosgel® treatment for a further 8
weeks. At the end of the open-label treatment phase, all
participants will return to standard care; however, those
who responded to open-label treatment will receive a
follow-up call 8 weeks later.
The study will involve four study visits and one to two
follow-up calls: screening visit (− 2 weeks), baseline visit
(0 weeks), follow-up call (2 weeks), follow-up visits at
weeks 8 and 16 and a follow-up call at week 24 (only for
participants who responded to open-label treatment).
Eligibility criteria
Inclusion criteria
At screening visit, the following criteria must be met:
1. Written informed consent
2. Irritable bowel syndrome with diarrhoea (IBS-D)
according to Rome IV criteria [3]
3. Aged 16–75 years
4. Considered suitable to take part in the study by the
consenting investigator
At baseline visit, before starting the intervention, the
following additional criteria must be met:
1. Diary completed on at least 11 of 14 days (≥ 75%)
during the screening period
Exclusion criteria
At screening visit, the participant will not be eligible to
proceed if they meet any of the following criteria:
1. Previously diagnosed coeliac disease (must be
confirmed from medical records before
randomisation)
2. Previously diagnosed IBD (must be confirmed from
medical records before randomisation)
3. Previous bowel cancer or bowel resection (must be
confirmed from medical records before
randomisation)
4. Other previously known gastrointestinal disorder
contributing to the diarrhoea according to principal
investigator’s or sub-principal investigator’s evalu-
ation (must be confirmed from medical records be-
fore randomisation)
5. Unexplained weight loss
6. Unexplained rectal bleeding (not including a short
history of typical haemorrhoidal bleeding in patients
aged < 45 years)
7. Previous use of Enterosgel®
Fig. 1 Study design
Kemppinen et al. Trials          (2020) 21:122 Page 3 of 14
8. Use of antidepressant agents, unless used at a stable
dose for at least 6 weeks
9. Use of any probiotic supplements, other intestinal
adsorbents (activated charcoal, kaoline,
diosmectite), slow-release medications or strong
opioids (World Health Organisation Step III) (must
be confirmed from medical records before
randomisation)
10. Participation in any research where treatment is
provided, or was provided in the last 3 months
11. Pregnancy or not willing to use contraception for
the duration of the study screening and treatment
periods
At baseline visit, the participant will not be eligible to
proceed to randomisation if they no longer meet one or
more of the criteria above, or if they demonstrated:
1. Loose stools (Bristol Stool Form Scale (BSFS) 6 or
7) on less than 3 days during the 14 days after
screening visit, and/or
2. Average abdominal pain < 3 during the 14 days after
screening visit (scale 0–10: 0 = no pain; 10 = worst
possible pain).
Interventions
Experimental intervention
The commercially available Enterosgel® product contains
30% water and 70% polymethylsiloxane polyhydrate
(PMS-PH), which is a three-dimensional crosslinked poly-
mer of methylsiliconic acid formed by polycondensation
in which hydroxyl groups form stable siloxane bonds.
Since over-the-counter Enterosgel® is instructed to be
taken by diluting 1–1.5 tablespoons of the product in
100–200ml water, a water-based placebo offers an alter-
native to a gel-like placebo. In order to enable a water-
based placebo to be used as a comparator in this trial, the
blinded Enterosgel® will be provided in a pre-diluted form
in 90-ml tubes containing 15 g Enterosgel® in 67.5ml pot-
able water. The placebo will be provided in the same 90-
ml tubes, each containing a single dose of treatment.
Study-specific dosage instructions for the double-blind
treatment period allow participants to adjust their daily
dosage based on their symptoms (Additional file 1).
For the open-label treatment phase, all participants
will receive Enterosgel® in standard 15-g sachets, which
are identical to those available over-the-counter in the
UK. Study-specific dosage instructions also allow partici-
pants to adjust their daily dosage based on their symp-
toms (Additional file 2).
Packaging, labelling and supply
Both the placebo and Enterosgel® dilutions for double-
blind treatment phase are manufactured in accordance
with Good Manufacturing Practice (GMP) by Bioline
Products s.r.o. (CZ), packed into identical 90-ml tubes
and labelled in accordance with Annex I of the European
Council Directive 93/42/EEC concerning Medical De-
vices. All study treatment will be stored at a Medicines
and Healthcare products Regulatory Agency (MHRA)-
approved warehouse facility (Wasdell Group, UK). After
each randomisation, the site research team will email a
request form with a unique randomisation code to a
dedicated email address, which can only be accessed by
Sponsor’s (Enteromed Ltd, UK) unblinded study coordi-
nators. A coordinator will check the randomisation code
against a pre-generated randomisation code list to deter-
mine whether it corresponds to placebo or Enterosgel®
and will then submit a shipment request to the ware-
house through a secure online portal. Supplies will be
dispatched for delivery directly to the study participants
within two calendar days from receiving the request
(next day delivery for orders submitted before 2 pm).
The supplied treatment will be sufficient to cover the
entire 8-week treatment phase even if the maximum
dose is taken every day.
Open-label treatment will be provided in sachets con-
taining 15 g Enterosgel® and labelled in accordance with
regulatory requirements. After a participant has been en-
tered into the open-label phase, the site research team
will send a treatment request to the Sponsor who will
submit a shipment request to the warehouse as
described above.
Treatment use and compliance are monitored through
the daily study diary where the patients are asked to rec-
ord how many doses of study treatment they used each
day. If they did not take any treatment on a given day,
then the electronic diary would also ask to provide a rea-
son. These data are monitored by the study team on a
weekly basis and the site teams are contacted if any is-
sues are identified. Participants are not required to re-
turn any empty or unused tubes or sachets. Should the
participant run out of study treatment during the study,
they can request additional supplies through their re-
search site.
Concomitant interventions
Participants will be allowed to continue to take anti-
depressant agents at a stable dose, provided that they
had been taking a stable dose for at least 6 weeks before
providing written informed consent.
Use of probiotic supplements, other intestinal adsor-
bents (activated charcoal, kaoline, diosmectite), slow-
release medications or strong opioids will not be permit-
ted during the study. To minimise the risk that Enteros-
gel® could adsorb concomitant medications in the gut, it
will be recommended to leave at least 2 hours before
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and after taking the study treatment and taking any oral
medications.
Loperamide will be provided to all study participants
for use as a rescue medication during the double-blind
and open-label treatment phases. Participants will be ad-
vised not to make any significant changes to their diet
during the trial.
Outcome measures
Primary outcome measure
The primary outcome measure is the percentage of par-
ticipants defined as responders for abdominal pain and
stool consistency during at least 4 weeks in the 8-week
treatment period, where:
1) An “abdominal pain intensity weekly responder” is
defined as a participant who experiences a decrease
in the weekly average abdominal pain score of at
least 30% compared with baseline. The weekly
average abdominal pain score is derived by scoring
the worst pain experienced each day and taking the
average for 1 week.
AND
2) A “stool consistency weekly responder” is defined as
a participant who experiences a 50% or greater
reduction in the number of days per week with at
least one stool that has a consistency of BSFS type 6
or 7 compared with baseline.
A participant needs to be a responder for both abdom-
inal pain and stool consistency in the same week to be
considered a responder that week.
Secondary outcome measures
Secondary outcome measures for the double-blind treat-
ment phase and open-label treatment phase are:
1. Stool frequency (mean over 8 weeks and the last 4
weeks based on a daily question in the study diary).
2. Stool consistency assessed as average number of
days/week with Bristol Stool Scale type > 5 (mean
over 8 weeks and the last 4 weeks based on a daily
question in study diary, and percentage of
responders where responder is defined as a
participant with ≥ 50% reduction in this outcome
compared with baseline (i.e. screening period)).
3. Abdominal pain (mean over 8 weeks and the last 4
weeks based on a daily question in the study diary,
and percentage of responders where responder is
defined as a participant with ≥ 30% reduction in
abdominal score compared with baseline (i.e.
screening period)). Abdominal pain is scored on a
scale from 0 to 10, where 0 means no pain at all
and 10 means the worst possible pain imaginable.
4. Bloating (mean weekly score over 8 weeks and the
last 4 weeks based on a weekly question in study
diary). Scale of bloating is from 0 to 6, where 0
means bloating was not bothersome at all and 6
means bloating was greatly bothersome.
5. Urgency (mean weekly score over 8 weeks and the
last 4 weeks based on a weekly question in the study
diary). Scale of urgency is from 0 to 6, where 0
means no urgency at all and 6 means a very great
deal of urgency with bowel movements.
6. Adequate relief of global IBS symptoms (percentage
of participants based on a weekly question in study
diary).
7. IBS Severity Scoring System (IBS-SSS) score
(weekly questionnaire)
8. IBS-related Work Productivity and Activity
Impairment (WPAI:IBS; weekly questionnaire to
assess percentage work time missed due to IBS,
percentage impairment while working due to IBS,
percentage overall work impairment due to IBS,
percentage activity impairment due to IBS).
9. IBS Quality of Life (IBS-QOL) score (4-weekly
questionnaire)
10. Patient Health Questionnaire 12 Somatic Symptom
(PHQ-12 SS) scale (4-weekly questionnaire to assess
total score and individual symptoms headache (e.),
tiredness (n.) and sleep (o.))
11. Use of rescue medication, i.e. loperamide (total
number of days loperamide used each week and
average over 8 weeks based on a weekly question in
study diary)
12. Adverse events (percentage of participants reporting
serious adverse event (SAE) and adverse events
(AE) possibly related to treatment and total number
of SAEs and AEs reported)
Data for secondary outcome measures for the follow-
up phase will be collected at week 24 follow-up call
using an investigator questionnaire developed specifically
for this study. Data will only be collected from partici-
pants who reported adequate relief in the last 4 weeks of
the open-label treatment phase. The outcomes for the
follow-up phase are:
1. Maintenance of treatment benefit (percentage of
participants who report increased or maintained
treatment benefit at 8 weeks)
2. Enterosgel® use (percentage of participants who
report having used Enterosgel® during the
follow-up period; frequency of use in these
participants)
3. Loperamide use (percentage of participants who
report having used less loperamide during the
follow-up period than before the trial)
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Exploratory outcome measures
1. Qualitative and quantitative data for faecal
microorganisms and biomarkers will be collected at
baseline and at the end of double-blind treatment
period (week 8) in a subgroup of 20 participants
using GI-MAP™ assay (Invivo Clinical Ltd, UK)
(Additional file 3). Participants will be selected for
stool testing by the randomisation program at
four selected sites so that ten participants from each
treatment group will be tested. Data will be com-
pared between treatment groups at week 8. Week 8
data will also be compared to baseline in all partici-
pants. Depending on the findings, other analyses
might be performed in this exploratory dataset.
2. Qualitative and quantitative data for intestinal
motility, fluid volume, gas content and physiology
will be collected at baseline and at 4 weeks of open-
label treatment period in a subgroup of 16 partici-
pants using magnetic resonance imaging (MRI;
Additional file 4). MRI data will be analysed using
GIQuant image processing software (Motilent Ltd,
UK). Only participants recruited to the main study
from the University Hospital of North Durham and
Newcastle Upon Tyne Hospitals will be invited to
take part in this assessment.
Study procedures
Participants will attend four study visits and receive one
to two follow-up calls from their local research team.
The schedule of visits and procedures conducted at each
visit are summarised in Fig. 2.
Screening visit (− 2 weeks)
Informed consent will be obtained before any trial-
specific procedures take place. Eligibility will then be de-
termined against all criteria except for the stool
consistency and abdominal pain criteria, which will be
determined over the next 2 weeks using an electronic
diary or a paper diary (for participants unable or unwill-
ing to use the electronic diary). In addition, if a partici-
pant is of childbearing potential, a pregnancy test should
be conducted after the 2-week screening period if a par-
ticipant is confirmed to be eligible. Any criteria related
to medical history or medication use that cannot be con-
firmed from the participant’s medical records at screen-
ing due to these not being available to the research
team, can be initially assessed based on participant-
reported information. However, such eligibility criteria
must be confirmed against the participant’s medical
notes before the participant is randomised. Vital signs
(pulse, blood pressure) should be taken and confirmed
to be within the following ranges: systolic blood pressure
90–140 mmHg; diastolic blood pressure 50–90mmHg;
heart rate 50–105 beats per minute.
Demographic data and current medical conditions and
concomitant medications should be recorded in the elec-
tronic case report form (eCRF).
If the participant passes all the screening steps above,
they are asked to complete a daily diary for 14 days to
record stool consistency and abdominal pain. Training
on how to use the electronic diary will be provided. If a
participant is not able or willing to use an electronic
diary, they will receive a paper diary containing identical
questions. The participants will be instructed not to use
any antidiarrhoeal medication during the screening
period.
If the participant fails screening due to lack of screen-
ing phase symptoms, they can be re-screened once if the
investigator believes the level of symptoms during the
initial screening period were atypical for them and that
there is a likelihood of achieving symptom thresholds on
a further attempt. Participants should not be informed
of the detailed reason(s) for why they failed screening in
order not to influence their responses if re-screened.
There should be a minimum of 2 weeks from failing
screening to re-screening. Participants can be enrolled
into re-screening remotely with a phone call unless they
need to be re-consented (i.e. if patient information has
changed). Participants can also be re-screened once if
their vital signs were outside accepted range at initial
screening.
Baseline visit (week 0)
After the 14-day screening period, screening diary data
will be reviewed to check eligibility against the diary-
based eligibility criteria. If an electronic diary was used,
the diary system will automatically evaluate eligibility. If
a paper diary was used, the site investigators should
enter the diary data in the electronic database to allow
the system to evaluate eligibility. A negative pregnancy
test must also be obtained from any female participants
of childbearing potential. Participants whose eligibility is
confirmed will complete study questionnaires (IBS-SSS,
IBS-QOL, PHQ-12 SS, WPAI:IBS) and be randomised to
blinded treatment. Participants will also receive a pack
of paper questionnaires (IBS-SSS, IBS-QOL, PHQ-12 SS,
WPAI:IBS) to complete at home during the treatment
phase. In total, 20 study participants at selected research
sites will be selected by the randomisation program for
stool sample testing. A separate consent will be sought
for the provision of stool samples. The selected partici-
pants who consent, will be provided with a stool sample
kit and a pre-paid postage envelope to post the sample
to the central laboratory where the samples will be
analysed. Participants recruited to the main study from
pre-selected sites will be invited to take part in MRI
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assessment. These participants will be provided with a
separate MRI information sheet at baseline visit and will
have the opportunity to discuss the assessment with the
research team and ask any questions before deciding
whether they wish to consent to MRI by signing a separ-
ate written informed consent form. If a participant de-
cides not to consent to stool sample testing or MRI
assessment, this will not affect their participation in the
main study. Participants who consent to MRI will
undergo two scans: at baseline (although not necessarily
on the same day as the baseline visit) and 12 weeks later,
i.e. after 4 weeks of open-label treatment. The scans will
take place at Newcastle Upon Tyne Hospitals and will
not last longer than 20min involving structural and mo-
tility (cine) imaging.
Follow-up call (week 2)
The site research team will contact the participants to
ensure that they are continuing in the study and discuss
any potential issues with the diary, questionnaires or the
study treatment. No data will be recorded on this call,
except for any reported AEs or changes in medical his-
tory or medications.
Follow-up visit 1 (week 8)
Participants will complete study questionnaires (IBS-
SSS, IBS-QOL, WPAI:IBS, PHQ-12 SS), and AEs and
changes in medical history and medications will be
reviewed. All participants will receive instructions on
how to take Enterosgel® for the next 8 weeks (open label
phase). Participants will also be provided with copies of
the paper questionnaires for the next 8 weeks. Those
participants selected for stool sample testing at baseline
will receive a stool sample kit.
Follow-up visit 2 (week 16)
Participants will complete study questionnaires (IBS-
SSS, IBS-QOL, WPAI:IBS, PHQ-12 SS), and AEs and
changes in medical history and medications will be
reviewed. All participants will be asked the following
question (replying (a) yes or (b) no): With regard to your
IBS symptoms, compared with the way you felt before
you started study treatment, have you, in the past 4
weeks, had adequate relief of your IBS symptoms? Those
participants who respond yes will receive a follow-up
phone call in 8 weeks. Those who respond no will re-
ceive no further follow-up from the research team and
will complete the study at this visit.
Follow-up call (week 24)
The site research team will contact those participants
who had received adequate relief from the open-label
treatment for a brief follow-up interview (see “Follow-up
visit 2 (week 16)” section above). Any AEs and changes
in medical history and concomitant medications will be
recorded.
Sample size estimation
The sample size calculation was based on demonstrating
superiority for the primary outcome, i.e. response to
treatment, with 90% power at 5% significance level. As-
suming a response rate of 20% in the placebo group and
35% in the active treatment group, 182 participants per
treatment group are required. Assuming 15% drop-out
rate, in total 430 participants will need to be enrolled.
The response rate of 20% in the placebo group is based
on previous studies [31, 32]. The sample size was calcu-
lated using a power calculator for binary outcome super-
iority trial (Sealed Envelope Ltd).
Recruitment
The study will be conducted at approximately 30 pri-
mary and secondary care sites and private gastrointes-
tinal clinics in England. GP surgeries acting as patient
identification centres will also refer patients to partici-
pating research sites. Sites will identify potential partici-
pants opportunistically and through searches of their
patient databases, waiting lists, case records and refer-
rals. Some research sites will utilise advanced software
(Clinithink Ltd, UK) to identify potentially eligible pa-
tients from their clinical databases. The study can be ad-
vertised at participating sites and in public with
materials approved by the Research Ethics Committee
and the Health Research Authority. The study has devel-
oped a dedicated website which enables the public to
check if they may be eligible and locate the contact de-
tails of their closest participating site. Finally, the study
will recruit through the ContactME IBS registry [33],
which contacts potentially eligible patients with details
of the study. All potentially eligible patients will be pro-
vided with a patient information sheet either when visit-
ing the GP/hospital/clinic or by post or email. Patients
should be allowed at least 24 h to consider the study in-
formation before they are consented into the study.
Randomisation
Eligible participants will be randomised by a delegated
member of the site research team to a double-blind
treatment group (placebo or interventional) in a 1:1 ra-
tio. Randomisation will be performed using a computer-
based online randomisation tool (Sealed Envelope Ltd,
UK). The randomisation algorithm is based on the mini-
misation method where treatment allocation is stratified
by study centre.
Blinding
Participants randomised to the control group will receive
placebo for 8 weeks. Participants randomised to the
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interventional group will receive Enterosgel® pre-diluted
in water for 8 weeks. Both the participants and the re-
search teams will be blinded to the treatment allocation
until the end of the study.
Unblinding
Unblinding (code-break) should only be performed dur-
ing the trial in a situation where information about the
participant’s trial treatment is necessary in order to pro-
vide appropriate and optimal medical care. Requests for
unblinding will first be reviewed by the principal investi-
gator (PI) or sub-PI who evaluates the information and
the importance of unblinding in the given circum-
stances. If they decide that unblinding is necessary to en-
sure appropriate medical care, an unblinding request
form should be submitted through the eCRF system.
Unblinded treatment allocation will then be sent to the
person who requested the unblinding. In case of emer-
gency unblinding, the PI will be responsible for deciding
whether the participant should continue on trial treat-
ment. Unblinded participants should be followed up ac-
cording to the study protocol until the end of the study.
Data management
Data capture
Data on IBS symptoms and treatment use will be col-
lected using a study-specific diary, which will be avail-
able as an electronic version developed by Sealed
Envelope Ltd (UK). The electronic diary can be com-
pleted online by following a link provided on daily email
and text message notification. For participants who are
not able or willing to use the electronic diary, a paper
diary will be provided. Copies of the paper diary are also
provided as a back-up to participants using the elec-
tronic diary. For double-blind and open-label diaries
completed on paper, the Sponsor’s research team will
complete data entry into the electronic diary database.
Study data recorded on any other paper source docu-
ments (e.g. questionnaires) will be transferred by the site
investigators to an eCRF developed by Sealed Envelope
Ltd (UK). The eCRF will be accessible via Internet
browser and will be password protected to ensure that
only authorised site staff and research team members
can enter the system to view, add or edit data according
to their permissions. Source data will be available at the
site to document the existence of the study participants
and will include the original documents relating to the
study (demographics, medical history, medication, in-
formed consent forms, questionnaires).
Analysis and archiving
After eCRF data entry is completed, all data have been
monitored and raised queries have been resolved, the
database will be locked. The complete exported dataset
will be transferred to the statistical programmers who
will complete the analyses in accordance with the Statis-
tical Analysis Plan. All essential documents and trial data
will be held by the sponsor for a minimum of 5 years
after the end of the trial. Investigator site files will be ar-
chived at the participating sites for 5 years.
Data monitoring
The study will be conducted in accordance with the
current approved protocol, International Conference of
Harmonisation (ICH) Good Clinical Practice (GCP)
guidance, relevant regulations and standard operating
procedures. Regular monitoring will be performed in ac-
cordance with the ICH GCP and a risk-based trial moni-
toring plan to evaluate compliance with the protocol
and accuracy in relation to source documents. In
addition, data will be regularly monitored for complete-
ness and quality using automated programmed edit
checks. Any data issues are raised as queries in the eCRF
system by study monitors.
An independent Data Monitoring Committee (DMC)
will monitor data collected during the study for efficacy
outcomes and safety. If any issues emerge, the DMC will
make recommendations regarding the continuation of
the study.
Statistical analyses
Detailed methodology statistical analyses of study data
will be documented in a statistical analysis plan. This
trial will be reported according to the CONSORT guide-
lines for clinical trials.
Planned analyses
Analyses will be conducted following intention-to-treat
(ITT) principles with outcomes analysed according to
the participant’s original, randomised group irrespective
of deviations based on non-compliance. The statistician
will remain blind to allocation until after the trial is
complete and data locked.
All participant baseline data will be summarised descrip-
tively by trial arm. Continuous measures will be reported
as means and standard deviations while the categorical
data will be reported as counts and percentages.
The primary outcome measure is the percentage of
participants defined as study period responders. Where
necessary, multiple imputation will be used to impute
missing daily abdominal pain and stool consistency
scores before the required derived variables are gener-
ated (see “Missing data” section below for further de-
tails). Once obtained, the primary outcome data will be
summarised descriptively and logistic regression will be
used to compare the placebo and Enterosgel® groups,
with odds ratio and 95% confidence interval reported.
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Secondary outcome data will be summarised descrip-
tively at different time points by trial arm. The second-
ary outcomes will be analysed using either analysis of
covariance (ANCOVA) models (for stool consistency
and abdominal pain following multiple imputation), lin-
ear mixed effects models (continuous secondary out-
comes), or mixed effects logistic regression models
(binary secondary outcomes). The mixed effects models
will contain indicator variables for treatment group and,
where appropriate, time plus a time-treatment inter-
action. The models will be adjusted for the baseline
measure of the outcome, where available.
Significance tests will be two-sided at the 5% signifi-
cance levels unless otherwise stated. All models in the
analysis of the double-blind and open-label phases will
be adjusted for participant’s age and gender at baseline.
Analyses will be undertaken in Stata v13 or later (to be
confirmed in the final report).
Missing data
Multiple imputation by chained equations will be used
to impute missing values in daily abdominal pain and
stool consistency scores before the primary outcome is
derived. A sensitivity analysis will be undertaken to com-
pare the results using multiple imputation with a
complete case analysis. The complete case analysis will
only use abdominal pain and stool consistency data
where participants provided scores on all 7 days within a
week (i.e. weeks containing at least one missing value of
abdominal pain/stool consistency will be excluded).
Quality assurance and control
The PI will be responsible for ensuring that the site is
complying with the study protocol, current version of
the World Medical Association Declaration of Helsinki,
ICH-GCP guidelines and the applicable regulatory re-
quirements. The PI will be responsible for ensuring that
all site staff involved in the study have been appropri-
ately trained and are qualified to conduct their delegated
tasks. All medical staff involved in this study are re-
quired to have a certificate in GCP.
Data handling and record-keeping/archiving
All study-related paper documents (e.g. paper diaries,
questionnaires, consent forms, study logs) will be filed in
the study files during the study and archived at the site
for 5 years after the end of the study.
Case report forms and source data
Data will be recorded in the eCRF from source docu-
ments defined in source data agreement with each site.
All participants receive a unique study identification
number (participant study ID) and no identifying data
such as name, initials or date of birth will be collected in
the eCRF. Source data will be available at the sites for
monitoring and auditing purposes. Source data will in-
clude the original documents relating to the study, in-
cluding demographics, eligibility checklists, informed
consent forms and study questionnaires.
Record-keeping and archiving
All essential documents and trial data will be held by
the sponsor for a minimum of 5 years after the end
of the trial. Investigator site files should be archived
at the participating sites for 5 years and should not be
destroyed until authorisation to do so has been re-
ceived from the sponsor.
Monitoring
Monitoring will be performed according to a risk-
based, study-specific trial monitoring plan by moni-
tors delegated by the sponsor. Monitoring includes
checking participant eligibility criteria for all partici-
pants and confirming that data have been recorded
correctly in the eCRF and any SAEs have been cor-
rectly reported and recorded.
Audits and inspections
All study documentation will be accessible to auditors
and inspectors. All involved parties must keep the
participant data strictly confidential. The Sponsor will
conduct internal audits in accordance with a study
audit plan.
Confidentiality and data protection
Access to source documents and other essential study
documents will be permitted for purposes of audits and
inspections. The study participants have consented to
relevant sections of their medical notes and data col-
lected during the study to be looked at by the research
team, by individuals from Enteromed Ltd or contracted
by Enteromed Ltd, from regulatory authorities or from
the National Health Service (NHS) Trust, where it is
relevant to this research. Participants have also con-
sented to their name, home address and phone number
being shared with Enteromed Ltd, and for Enteromed
Ltd to provide this information to a study supplies ware-
house and a courier company for the purposes of deliv-
ery of the study treatment. No identifiable data will be
collected in the eCRF or will be published in any ab-
stracts or publications resulting from the study.
Biological materials
Stool samples will be taken by the selected participants
at home using a provided kit that includes a postage en-
velope for sending the sample to the central laboratory
where the samples will be received within 6 days from
collection and immediately stored at 4 °C upon arrival in
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the laboratory. Protein aliquots will be prepared within
24 h of receipt and stored at − 20 °C until testing within
3 days. All protein testing will be performed using stand-
ard enzyme-linked immunosorbent assay (ELISA) meth-
odology. Nucleic acids will be isolated from samples
within 1–2 business days after sample receipt and iso-
lated nucleic acids will be immediately stored at − 80 °C
until testing. Analysis reports will be uploaded by the la-
boratory onto a secure online portal accessible by the
sponsor’s research team. Results will not be shared with
the research sites or the study participants. The stool
samples will be destroyed by the central laboratory after
the samples have been analysed.
Safety assessments
Types of AEs associated with medical devices and ap-
plicable for this study are defined in accordance with the
European Commission guidelines on medical devices
[34]. AEs will be collected throughout the study from
screening visit until week 24. The following information
will be recorded for all AEs: medical term of the AE
(SNOMED CT terminology), start date and date of reso-
lution, seriousness, severity, study treatment action, out-
come, relationship with the study treatment and
expectedness. In case of a SAE related to study treat-
ment(s) or procedures, the participant should be with-
drawn from the study. Expectedness will be determined
based on known side effects listed on the latest Instruc-
tions for Use for Enterosgel®. Currently listed known side
effects of Enterosgel® are nausea and constipation.
Reporting of serious adverse events and other safety-
related events
The sponsor must report all SAEs, whether initially con-
sidered to be device-related or not, immediately to the
MHRA. The Research Ethics Committee should be noti-
fied of any related and unexpected SAEs within 15 days.
Reports of related and unexpected SAEs in double-blind
trials should be unblinded. However, local investigators
should only receive information on the code-break if it
is necessary for the safety of the participant.
AEs suspected to be related only to an authorised auxiliary
medicinal product (i.e. loperamide), and not resulting from
a possible interaction with the investigational treatment,
should be reported through the Yellow Card Scheme.
Discussion
We present a protocol and study design for a multi-
centre, randomised, double-blind, placebo-controlled
trial with an open-label treatment phase. The primary
objective of this trial is to determine whether treatment
with Enterosgel® has a positive effect on IBS symptoms
in patients with IBS-D, including stool consistency and
abdominal pain.
Although Enterosgel® is already available in many
countries over the counter, this is the first clinical trial
in IBS-D with Enterosgel® and a placebo control arm. As
many patients with IBS do not get adequate relief of
their symptoms with existing treatments, we wanted to
design a trial where all study participants would get an
opportunity to try the active treatment. We therefore in-
cluded an 8-week open-label treatment phase where all
participants receive Enterosgel®. This study design is
likely to increase participation and study completion
rates, and also allows us to evaluate the impact of Enter-
osgel® in participants randomised to the placebo arm for
the double-blind phase.
Enterosorbents or the more recently termed “oral in-
testinal adsorbents” are a group of materials with sorp-
tion properties which include activated carbons,
inorganic minerals and polymeric and silicon-containing
resins. They have been widely used in Commonwealth
of Independent States countries for decades but are less
well known or utilised by healthcare professionals or the
general public in the west. One of the reasons behind
this disparity may be easier access in the west to
pharmaceutical interventions. Enterosgel® has been used
to treat a wide range of conditions from acute intestinal
infections to side effects of chemo- and radiotherapy, al-
though many of the supporting studies have intrinsic
limitations with regards to methodological design and
reporting. Currently, there is need for more high-level
RCTs on intestinal adsorbents; this will help encourage
their uptake, inform our understanding of their action
and may have implications regarding their use as anti-
biotic alternatives and in other gastrointestinal diseases.
One of the main challenges in clinical trials in IBS is
that the placebo response is typically large; placebo re-
sponse rates as high as 37.5% have been reported [35].
Suggested methods to reduce placebo response include:
adding a run-in phase to exclude high-responders to
placebo; assessment of anxiety and depression at
baseline (may be particularly important in studies of
IBS); reducing the frequency of intervention and opti-
mizing and standardizing patient–physician relation-
ships. However, none of these strategies have clearly
shown to be effective and some may not be possible to
implement in all types of studies. For example, limiting
patient–physician interaction might not be appropriate
in a real-world setting, while prescribing low frequency
therapy is not possible without also reducing the treat-
ment effect of active treatment. We have addressed the
issue of placebo response in our sample size calcula-
tion, which assumes a 20% response rate in the placebo
group. The overall response rate in the total sample will
be monitored throughout the trial by a DMC so that
measures can be taken if the response rate is not con-
sistent with our pre-trial assumptions.
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Another challenge for IBS trials is that there are no ob-
jective outcome measures. We will use a patient-reported
primary outcome measure recommended by the US Food
and Drug Administration (FDA) and the European Medi-
cines Agency (EMA) for clinical trials in IBS [36, 37].
While this outcome measure is subjective, using a standar-
dised recommended measure will enable the results from
this trial to be more easily compared to findings from
other trials. As the study primary outcome measure relies
on daily completion of study diaries, in collaboration with
Sealed Envelope Ltd we developed an electronic online
diary that the participants can easily complete on their
own mobile phone, tablet or computer by simply follow-
ing daily text message and/or email links, which also serve
as reminders. However, a paper diary will also be available
so that participants can choose the option that works best
for them. The content of the diaries was carefully consid-
ered in order not to overburden participants and, as a re-
sult, some of the questions will only be completed weekly
to minimise the time participants need to spend on com-
pleting the diary each day.
The primary outcome measure evaluates the impact
on the key IBS features of stool consistency and abdom-
inal pain, but IBS can also present as various other
symptoms. To assess other aspects of IBS and to allow
further comparison of our results to those from other
studies, we have also included secondary outcome mea-
sures that are commonly used in clinical trials in IBS
(e.g. IBS-SSS and IBS-QOL). In addition, we have in-
cluded exploratory measures (stool analyses, MRI) to
allow us to explore the effects of Enterosgel® on a
physiological level.
Possibly the greatest challenge for IBS trials performed
in the UK is recruitment to time and target. Despite be-
ing a common condition, it has proved surprisingly diffi-
cult to recruit effectively to trials and there are probably
a number of reasons for this:
1. Although IBS is common, patients are often
discharged from regular follow-up, so there is little
rapport with the research team.
2. Patients are not found in one ‘place’ within the
NHS service, but are dispersed.
3. Patients in secondary care who remain in follow-up
often have complex illness, with severe refractory
symptoms or comorbid conditions. These patients
are not ideal participants for trials.
4. Patients are often reluctant to come off laxatives/
loperamide and are not keen to risk being on placebo.
5. There is a likelihood that patients with chronic
illness of moderate severity are less willing to
undertake trial burden compared to, for
example, cancer trials where the treatment may
be life-saving.
To mitigate these challenges the trial was designed
with the patient in mind. Extensive patient feedback was
obtained on all parts of the protocol, something that is
relatively unusual in commercially sponsored trials. The
protocol was reviewed by the Durham BRAG (Bowel Re-
search patient Advisory Group). One of the important
outcomes of that was the need for an open label phase.
As one patient put it: “Why would I join a trial and have
a chance of just being on placebo when I can go to the
chemist and buy the treatment for myself”. The group
also emphasized the importance of a low visit burden
(many IBS patients are of working age) and the need for
rescue therapies. In a separate meeting a group of pa-
tients completed the trial diaries and questionnaires and
timed themselves. This led to a reduction in the ques-
tionnaire burden and a simplification of the diaries. In a
separate survey of 55 consecutive patients attending the
Chief Investigator’s outpatient clinic the patients were
given a small audit questionnaire asking their views on
their ownership of smartphones, access to internet and ac-
ceptability electronic diaries. This encouraged the use of
an electronic diary with text-based reminders. Patients be-
ing treated with the product in advance of the trial starting
were asked to comment on dose-modifying instructions.
We also took advice from GPs to make sure the inclu-
sion and exclusion criteria were pragmatic and suitable
for primary care recruitment.
We will use various channels to advertise the trial lo-
cally and nationally, including using social media, have
set up a dedicated study website with a list of recruiting
sites and will recruit participants through a UK-based
IBS registry, ContactME-IBS [33]. Some of the research
sites will use an advanced software (Clinithink Ltd, UK)
to identify potentially eligible patients. As IBS is a condi-
tion that in the UK is mainly treated in the primary care
setting or self-managed with over-the-counter products,
our study inclusion and exclusion criteria are pragmatic
and we expect our study population to be representative
of the real-life population of patients with IBS. If found
to be effective, Enterosgel® can offer a new treatment op-
tion for IBS-D and encourage future clinical trials in
other related conditions.
Trial status
The trial started enrolment in November 2018, with the
first patient consented 27 days after all required ap-
provals for the study protocol had been received and 8
days after site activation. This has been updated to May
2020. The latest protocol version is v.3.0 dated 23 Janu-
ary 2019. All substantial protocol amendments have
been submitted to the North East – Tyne & Wear South
Research Ethics Committee, who approved the study,
and to the MHRA and HRA. All non-substantial amend-
ments have been submitted to the MHRA and HRA.
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